Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
暂无分享,去创建一个
Robert Pirker | K. O'Byrne | Keunchil Park | R. Ramlau | M. Krzakowski | U. Gatzemeier | J. R. Pereira | J. Roh | Chih-Teng Yu | R. Pirker | A. Szczesna | I. Vynnychenko | W. Eberhardt | Keunchil Park | Kenneth O'Byrne | Ulrich Gatzemeier | Aleksandra Szczesna | Joachim von Pawel | Michael Emig | E. Bajetta | Maciej Krzakowski | Rodryg Ramlau | Emilio Bajetta | Ihor Vynnychenko | Wilfried Eberhardt | J. Pawel | V. Ganul | F. Marinis | T. Goddemeier | M. Emig | Jose R Pereira | Chih-Teng Yu | Valentyn Ganul | Jae-Kyung Roh | Filippo de Marinis | Thomas Goddemeier
[1] A. Ardizzoni,et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. , 2007, Journal of the National Cancer Institute.
[2] Roy S Herbst,et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Xin Li,et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Christopher U. Jones,et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.
[5] G. Giaccone,et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Clarke. Individual patient data meta-analyses. , 2005, Best practice & research. Clinical obstetrics & gynaecology.
[7] Thomas J. Smith,et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] N. Hanna,et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] N. Hanna. Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial , 2008 .
[10] F. Shepherd,et al. Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer , 2007 .
[11] J. Crowley,et al. Concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in advanced non-small cell lung cancer (NSCLC): A randomized phase II selectional trial SWOG 0342. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Mendelsohn,et al. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. , 1994, The Journal of biological chemistry.
[13] S. Ramalingam,et al. Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced‐stage nonsmall cell lung cancer , 2008, Cancer.
[14] Edward S. Kim,et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial , 2008, The Lancet.
[15] T. Lynch,et al. B3-03: A randomized multicenter phase III study of cetuximab (Erbitux®) in combination with Taxane/Carboplatin versus Taxane/Carboplatin alone as first-line treatment for patients with advanced/metastatic Non-small cell lung cancer (NSCLC) , 2007 .
[16] J. Baselga,et al. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. , 1993, Cancer research.
[17] D. Gandara,et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] J. Mendelsohn,et al. Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma , 1993, Cancer Immunology, Immunotherapy.
[19] P. Ellis,et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] G. Giaccone,et al. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] F. Shepherd,et al. Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] R. Pearson,et al. Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer , 2010 .
[23] C. Bokemeyer,et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. , 2008, The New England journal of medicine.
[24] J. Mendelsohn. Targeting the epidermal growth factor receptor for cancer therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] L. Tanoue,et al. Erlotinib in Previously Treated Non-Small-Cell Lung Cancer , 2007 .
[26] John D Minna,et al. New molecularly targeted therapies for lung cancer. , 2007, The Journal of clinical investigation.
[27] R. Herbst,et al. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.